<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3389/fimmu.2019.00809</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Response Modifiers: Tweaking the Immune Response Against Influenza A Virus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elbahesh</surname><given-names>Husni</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/676310/overview"/></contrib><contrib contrib-type="author"><name><surname>Gerlach</surname><given-names>Thomas</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/713969/overview"/></contrib><contrib contrib-type="author"><name><surname>Saletti</surname><given-names>Giulietta</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/713972/overview"/></contrib><contrib contrib-type="author"><name><surname>Rimmelzwaan</surname><given-names>Guus F.</given-names></name><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/593655/overview"/></contrib></contrib-group><aff><institution>Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine (TiHo)</institution>, <addr-line>Hanover</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Abhijeet Anil Bakre, University of Georgia, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Elisa Vicenzi, San Raffaele Hospital (IRCCS), Italy; Giulia Fabozzi, National Institute of Allergy and Infectious Diseases (NIAID), United States</p></fn><corresp id="c001">*Correspondence: Husni Elbahesh <email>husni.elbahesh@tiho-hannover.de</email></corresp><corresp id="c002">Guus F. Rimmelzwaan <email>guus.rimmelzwaan@tiho-hannover.de</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>4</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>809</elocation-id><history><date date-type="received"><day>10</day><month>1</month><year>2019</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Elbahesh, Gerlach, Saletti and Rimmelzwaan.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Elbahesh, Gerlach, Saletti and Rimmelzwaan</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Despite causing pandemics and yearly epidemics that result in significant morbidity and mortality, our arsenal of options to treat influenza A virus (IAV) infections remains limited and is challenged by the virus itself. While vaccination is the preferred intervention strategy against influenza, its efficacy is reduced in the elderly and infants who are most susceptible to severe and/or fatal infections. In addition, antigenic variation of IAV complicates the production of efficacious vaccines. Similarly, effectiveness of currently used antiviral drugs is jeopardized by the development of resistance to these drugs. Like many viruses, IAV is reliant on host factors and signaling-pathways for its replication, which could potentially offer alternative options to treat infections. While host-factors have long been recognized as attractive therapeutic candidates against other viruses, only recently they have been targeted for development as IAV antivirals. Future strategies to combat IAV infections will most likely include approaches that alter host-virus interactions on the one hand or dampen harmful host immune responses on the other, with the use of biological response modifiers (BRMs). In principle, BRMs are biologically active agents including antibodies, small peptides, and/or other (small) molecules that can influence the immune response. BRMs are already being used in the clinic to treat malignancies and autoimmune diseases. Repurposing such agents would allow for accelerated use against severe and potentially fatal IAV infections. In this review, we will address the potential therapeutic use of different BRM classes to modulate the immune response induced after IAV infections.</p></abstract><kwd-group><kwd>influenza</kwd><kwd>treatment</kwd><kwd>response modifiers</kwd><kwd>antiviral</kwd><kwd>immune response</kwd><kwd>immunomodulators</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Alexander von Humboldt-Stiftung<named-content content-type="fundref-id">10.13039/100005156</named-content></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="99"/><page-count count="8"/><word-count count="6562"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Influenza viruses (IVs) are responsible for significant morbidity and mortality in the human population with ~500,000 annual deaths worldwide. IVs can cause severe acute respiratory disease especially in high-risk populations like children, the elderly and the immunocompromised. While both influenza A and B viruses (IAV and IBV, respectively) cause annual epidemics, the majority of severe human infections are caused by IAV.</p><p>IVs have segmented negative-sense single-stranded RNA genomes. The lack of proof-reading activity of the viral RNA-dependent RNA polymerase (RdRp) and successive replication can lead to the accumulation of nucleotide mutations which drive antigenic drift. In addition, the segmented nature of their genome allows genetic reassortment between IV's to take place, which can produce novel strains that have acquired alternative antigenically distinct hemagglutinin, also known as antigenic shift. Both antigenic drift and antigenic shift contribute to the IV's ability to evade pre-existing host immunity induced by previous infections.</p><p>Early recognition and responses to IV infection are largely mediated by innate immune sensors expressed by its primary target, the alveolar epithelial cells (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Recognition of IVs is mediated by pattern recognition receptors (PRRs) that include Toll like receptors (TLRs), retinoinc acid inducible gene-I (RIG-I), and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3); all of which can recognize viral RNAs during various stages of the infection cycle (<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>). Activation of these sensors triggers signaling cascades that lead to the production of interferons as well as pro-inflammatory cytokines and chemokines ultimately resulting in an antiviral state within the surrounding cells/tissue (<xref rid="B6" ref-type="bibr">6</xref>). Accordingly, IVs have multiple mechanisms to evade these responses mediated by the viral nonstructural 1 protein (NS1), polymerase basic 1 protein (PB1), polymerase basic 2 protein (PB2), polymerase acidic (PA) and nucleoprotein (NP) [reviewed in van de Sandt et al. (<xref rid="B1" ref-type="bibr">1</xref>) and Chen et al. (<xref rid="B2" ref-type="bibr">2</xref>)].</p><p>In otherwise healthy individuals, IAV infections are mild and the ensuing pro- and anti-inflammatory responses are balanced. In contrast, a &#x0201c;cytokine storm&#x0201d; is typically associated with severe infections including those caused by highly pathogenic IV strains. During a cytokine storm, chemokine and cytokine responses are dysregulated in both intensity and kinetics resulting in excessive damage to the host due to infiltration of inflammatory immune cells. Acute lung injury (ALI) caused by this inflammatory response is typically characterized by significant damage or destruction of the respiratory epithelium leading to acute respiratory distress syndrome (ARDS) (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>).</p><p>Clinical treatment options for severe influenza virus infections remain limited and relying heavily on the administration of antiviral neuraminidase inhibitors (NAIs) and supportive critical care (<xref rid="B9" ref-type="bibr">9</xref>). However, NAIs have not been effective in patients with severe H7N9 or H5N1 infections and there is evidence that fatal outcomes are associated with development of antiviral resistance in patients (<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>). While virus-targeted therapies remain the standard approach, IV's mutability and adaptation to current antivirals has highlighted the need for new therapeutic options that target host factors that regulate IV infections and resulting immune responses. In either approach, the focus is to prevent or limit damage to the lung epithelium due to exaggerated or dysregulated immune cell responses. Biological response modifiers (BRMs) can alter the immune response thereby offering an additional therapeutic approach to treating severe infections. In this review, we highlight several studies that have shown the viability of BRMs as potential treatment options. For clarity, BRMs are categorized based on the type of biological agent (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Biological response modifiers discussed.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>BRM class</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Target</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Therapy</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Activity</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>IAV strain</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Therapeutic antibodies</td><td valign="top" align="left" rowspan="1" colspan="1">HA</td><td valign="top" align="left" rowspan="1" colspan="1">MHAA4549A, MEDI8852 and VIS410</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced viral replication. &#x02013; Improved symptoms of human patients in phase 2 clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Circulating seasonal (2015/16) IAV; Seasonal IAV (H3N2) challenge</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">ANGPTL4</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-ANGPTL4</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced pulmonary tissue leakiness, significantly accelerated lung recovery and improved lung tissue integrity in mice.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mouse-adapted laboratory IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B16" ref-type="bibr">16</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">C5a</td><td valign="top" align="left" rowspan="1" colspan="1">IFX-1 antibody</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced viral load and virus-induced ALI due to reduced infiltration of lung macrophages and neutrophils in IAV-infected African green monkeys.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Highly-pathogenic avian IAV (H7N9)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TRAIL</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Trail</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Increased survival rate following IAV infections in mouse studies.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mouse-adapted laboratory IAV (H1N1 and its derivative H3N2)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TNF&#x003b1;</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-TNF&#x003b1;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced disease burden in mouse studies. &#x02013; No effect on viral replication.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mouse-adapted laboratory IAV (H1N1-derived H3N2)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">20</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Therapeutic peptides</td><td valign="top" align="left" rowspan="1" colspan="1">AMP</td><td valign="top" align="left" rowspan="1" colspan="1">LL-37</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced morbidity and mortality to similar levels as zanamivir in mice.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mouse-adapted laboratory IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Influenza A virus</td><td valign="top" align="left" rowspan="1" colspan="1">TAT-K&#x003b1;2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Complete protection of infected mice. &#x02013; Direct virocidal activity.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Highly-pathogenic avian IAV (H5N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B22" ref-type="bibr">22</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Therapeutic small molecules</td><td valign="top" align="left" rowspan="1" colspan="1">JNK1/JNK2</td><td valign="top" align="left" rowspan="1" colspan="1">SP600125, AS601245</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced levels of pro-inflammatory cytokines and reduced viral titers in mice.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Highly-pathogenic avian IAV (H7N7); 2009 pandemic IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">p38</td><td valign="top" align="left" rowspan="1" colspan="1">SB202190, SB203580</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mice were protected from lethal H5N1 infection exhibiting reduced mortality and pro-inflammatory responses.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Highly-pathogenic avian IAV (H5N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MEK</td><td valign="top" align="left" rowspan="1" colspan="1">CI-1040</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced lung viral load and mortality of IAV-infected mice.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; 2009 pandemic IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NFkB</td><td valign="top" align="left" rowspan="1" colspan="1">SC75741</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced mortality and morbidity in mice following highly pathogenic IAV infections. &#x02013; Similar results prophylactically.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Highly-pathogenic avian IAV (H7N7 and H5N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B27" ref-type="bibr">27</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">GRK2</td><td valign="top" align="left" rowspan="1" colspan="1">Paroxetine</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Reduced viral load. &#x02013; No effect on mortality in IAV-infected mice.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; 2009 Pandemic IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">SphK1/SphK2</td><td valign="top" align="left" rowspan="1" colspan="1">SK-1I, SK-2I, and Pan-SKI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Prolonged survival of mice following lethal IAV infection.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mouse-adapted laboratory IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B29" ref-type="bibr">29</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">PAR1</td><td valign="top" align="left" rowspan="1" colspan="1">SCH79797</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Increased survival and a decrease in inflammatory responses in H5N1 or H1N1 infected mice. &#x02013; Similar effect when administered 48&#x02013;72 h after infection.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Mouse-adapted IAVs (H1N1 and H3N2); Oseltamivir-resistant 2009 pandemic IAV isolate (H1N1); highly-pathogenic avian IAV (H5N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">PPAR&#x003b1;/PPAR&#x003b3;</td><td valign="top" align="left" rowspan="1" colspan="1">Gemfibrozil (PPAR&#x003b1;), Pioglitazone (PPAR&#x003b3;)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Improved symptoms and increased survival of IAV infected mice. ed survival after H1N1 or H5N1 mouse infections.</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; 1957 Pandemic IAV (H2N2); mouse-adapted laboratory IAV (H1N1); 2009 pandemic IAV (H1N1)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="s2"><title>Biological Response Modifiers</title><sec><title>Therapeutic Antibodies</title><p>IAV infections and some vaccines elicit broadly-neutralizing antibodies (Abs) that target the viral HA-stem. However, their abundance and immune-subdominance is overshadowed by Abs targeting the HA-head domain. The effectiveness of these HA-stem Abs against a broad range of IAV subtypes, makes them an attractive target not only for vaccine development but also as antivirals. Indeed, several HA-stem specific human monoclonal Abs are now being evaluated in clinical trials [reviewed in Davidson (<xref rid="B34" ref-type="bibr">34</xref>)]. MHAA4549A, MEDI8852, and VIS410 are human monoclonal Abs that have been shown to control viral replication and improve symptoms of human patients in phase 2 clinical trials (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>).</p><p>While virus-specific Abs aim to reduce antigenic load, Abs to host targets aim at limiting the secondary wave of cytokines and reduce prolonged damaging cellular infiltration during severe infections. Host-target directed antibodies have been utilized to target key regulators of this inflammatory wave and could potentially be used to dampen these overt responses.</p><p>Angiopoietin-like 4 (ANGPTL4) is a soluble angiogenic-regulating protein. Following proteolytic cleavage, the C-terminal portion (cANGPTL4) is involved in integrin-dependent wound repair and can regulate vascular permeability (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). ANGPTL4 was significantly elevated in lung biopsies from IAV-induced pneumonia patients (<xref rid="B16" ref-type="bibr">16</xref>). In mouse studies, neutralizing anti-ANGPTL4 Abs reduced pulmonary tissue leakiness significantly accelerating lung recovery and improved lung tissue integrity (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Neutrophil infiltration into the alveolar space occurs within 1 day following IAV infections (<xref rid="B37" ref-type="bibr">37</xref>). Neutrophil extracellular traps (NETs) released during IAV-induced pneumonia into the alveolar space caused alveolar damage (<xref rid="B38" ref-type="bibr">38</xref>). The complement protein C5a was shown to induce NETs release and administration of anti-C5a Abs (IFX-1) reduced H7N9-induced ALI due to reduced infiltration of lung macrophages and neutrophils as well as reduction of viral load in African green monkeys (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B39" ref-type="bibr">39</xref>).</p><p>Tumor necrosis factor alpha (TNF&#x003b1;) is a key cytokine for controlling severe IAV infections. It regulates two main antiviral functions: the induction of (i) the NFkB pathway, which ultimately controls expression of several inflammatory cytokines and (ii) apoptosis through multiple signaling cascades (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). TNF upregulation during IAV infections correlates with infection severity, especially following highly pathogenic IAV-infections (<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>). Mice treated with anti-TNF Abs showed reduced disease burden; however, the authors of that study reported no effect on viral replication (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>TNF-related apoptosis inducing ligand (TRAIL) can trigger apoptosis in IAV-infected cells. IAV-infected human epithelial cells are sensitized to TRAIL-mediated apoptosis while peripheral blood mononuclear cells upregulate TRAIL expression. Moreover, administration of monoclonal Abs against TRAIL increases survival rate following IAV infections in mouse studies (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>).</p></sec><sec><title>Therapeutic Peptides</title><p>Antimicrobial peptides (AMPs) are host proteins that have direct antibacterial and antiviral activities and can modulate immune responses to infections. While the literature is largely focused on the antibacterial aspects of AMPs, several studies have highlighted the antiviral potential of AMPs against several viruses including IVs [reviewed in Hsieh and Hartshorn (<xref rid="B45" ref-type="bibr">45</xref>) and Albericio and Kruger (<xref rid="B46" ref-type="bibr">46</xref>)]. LL-37 is a human cathelicidin derived AMP that is found predominantly in neutrophils and its expression can also be induced in epithelial cells and macrophages (<xref rid="B47" ref-type="bibr">47</xref>). Aerosol administration of either human LL-37 or its mouse counterpart mCRAMP led to reduced morbidity and mortality to similar levels as the neuraminidase inhibitor zanamivir that is used for the treatment of human influenza patients (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Both cellular and viral FADD-like IL-1&#x003b2;-converting enzyme-inhibitory protein (cFLIP and vFLIP, respectively) protect cells from death receptor mediated apoptosis. K&#x003b1;2 is a vFLIP-derived peptide that consists of 10 amino acids from the &#x003b1;2 helix of the Kaposi's sarcoma herpes virus (KSHV) death effector domain 1 protein. A synthetic version of this peptide, TAT-K&#x003b1;2, was generated by fusing K&#x003b1;2 to a portion of the HIV TAT protein (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B48" ref-type="bibr">48</xref>). In mouse challenge studies, intranasal administration of TAT-K&#x003b1;2 at the time of infection with highly pathogenic avian H5N1 virus resulted in protection of the treated mice. No replicating virus was detected in the lungs at either 3 or 5 days after infection suggesting complete protection from infection (<xref rid="B22" ref-type="bibr">22</xref>). It should be noted that this effect is largely due to direct destabilization of the virions by the TAT-K&#x003b1;2 peptide and it is likely that infection in treated mice was not established; the efficacy of this AMP has not been determined during an established infection and warrants further investigation.</p></sec><sec><title>Therapeutic Small Molecules</title><p>Host kinases regulate not only IAV entry and replication but also initiate antiviral signaling cascades that regulate expression of pro-inflammatory chemokines and cytokines during infections and present viable targets for intervention (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B49" ref-type="bibr">49</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>).</p><p>IAV infection has been shown to upregulate c-Jun N-terminal kinases 1 and 2 (JNK1/JNK2). These kinases directly regulate the induction of pro-inflammatory responses. IAV-induced JNK1/JNK2 activation mediates production of chemokines and cytokines including TNF-&#x003b1;, interferon &#x003b2; (IFN-&#x003b2;), and interleukin 6 (IL-6) (<xref rid="B24" ref-type="bibr">24</xref>). <italic>In vivo</italic> inhibition of JNK1/JNK2 resulted in reduced levels of pro-inflammatory cytokines and reduced viral titers (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>).</p><p>The mitogen activated protein kinase (MAPK), p38, regulates viral entry and replication (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B59" ref-type="bibr">59</xref>). Furthermore, p38 regulates IFN stimulated gene (ISG) gene expression and ultimately cytokine production via STAT1 phosphorylation (<xref rid="B25" ref-type="bibr">25</xref>). Using either of two specific p38 inhibitors (SB 202190 or SB 203580), mice were protected from lethal H5N1 infection exhibiting reduced mortality and pro-inflammatory responses (<xref rid="B25" ref-type="bibr">25</xref>). Activation of another MAPK, MEK, is required for efficient IAV replication and its inhibition results in viral ribonucleoprotein (vRNP) retention and reduced titers of progeny virus (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>). Importantly, treatment of mice with the clinically approved MEK inhibitor (CI-1040) showed reduced lung viral load and mortality of mice following infection with a lethal dose of pandemic H1N1 IAV; interestingly, this inhibitor significantly out-performed the clinically recommended oseltamivir in these studies (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>Another central regulator of immune responses at the epithelium as well as immune cells is the NF-&#x003ba;B signaling pathway. Accordingly, IAV has evolved several mechanisms to modulate this pathway to counteract antiviral responses including directly targeting the IkB kinase (IKK) (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). SC75741 is a potent NFkB inhibitor that functions by reducing the ability of the p65 subunit of the NFkB complex to bind DNA; thereby limiting its transcription-regulating functions (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>). <italic>In vivo</italic> administration of SC75741 at 4 days after lethal infection with either H5N1 or H7N7 avian viruses resulted in significant protection with most mice surviving and showing little to no clinical symptoms; similar results were obtained by prophylactic administration (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>G-protein coupled receptor kinase 2 (GRK2) is best known for its phosphorylation of GPCRs in cardiac tissue resulting in recruitment of &#x003b2;-arrestin to facilitate rapid receptor internalization and lysozomal degradation (<xref rid="B66" ref-type="bibr">66</xref>). Recent phosphoproteomic studies identified GRK2 as a potentially proviral host protein for IAV that plays a major role in virion uncoating (<xref rid="B28" ref-type="bibr">28</xref>). Although <italic>in vivo</italic> inhibition of GRK2 using paroxetine led to a significant reduction in upper respiratory tract viral load and to a modest reduction in lower respiratory tract titers at 4 days post infection, this inhibition was not protective from lethal infections (<xref rid="B28" ref-type="bibr">28</xref>). However, it is possible that the route of administration (intraperitoneal vs. intranasal) and dosing regimen influenced the results.</p><p>Sphingosin kinases (SphK) are lipid kinases that mediate conversion of sphingosine to bioactive lipid sphingosine 1-phosphate (S1P) (<xref rid="B67" ref-type="bibr">67</xref>), a known modulator of central apoptotic pathways (<xref rid="B68" ref-type="bibr">68</xref>). IAV infections leads to increased expression and activation of SphK1 and SphK2 (<xref rid="B29" ref-type="bibr">29</xref>) and <italic>in vitro</italic> inhibition of SphK1 was shown to decrease IAV RNA synthesis via suppression of NFkB activation (<xref rid="B69" ref-type="bibr">69</xref>). Treatment of mice with specific inhibitors to either SphK1 or SphK2 or a pan-SphK inhibitor led to prolonged survival of mice following lethal IAV infection (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>Peroxisome proliferator-activated receptors (PPAR&#x003b1;, PPAR&#x003b2;, and PPAR&#x003b3;) regulate metabolic homeostasis and are important mediators of the inflammatory response. Several PPAR agonists have been investigated for efficacy during IAV infections with varying results. Gemfibrozil (PPAR&#x003b1; agonist) not only improved symptoms when administered 4 days after infections with an H2N2 virus, but also increased survival of IAV infected mice (<xref rid="B31" ref-type="bibr">31</xref>). Prophylactic treatment of H1N1-infected mice with pioglitazone (PPAR&#x003b3; agonist) resulted in increased survival (<xref rid="B32" ref-type="bibr">32</xref>). Combined activation of PPAR&#x003b3; and its downstream target AMPK improved survival of mice infected with pandemic IAV strains (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>Protease activated receptor (PARs) link protease activity to inflammatory cellular responses (<xref rid="B70" ref-type="bibr">70</xref>). PAR1 expression is upregulated in the mouse airways following IAV infections (<xref rid="B71" ref-type="bibr">71</xref>). Intranasal administration of a PAR1 antagonist (SCH79797) at the time of infection with various IAV strains including highly pathogenic avian H5N1 and pandemic H1N1 viruses led to increased survival and a decrease in inflammatory responses. Moreover, this effect was also observed when SCH79797 was administered 48&#x02013;72 h after infection (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>The use of statins, angiotensin II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEi) has been proposed to regulate the IAV-induced cytokine storm in severe infections (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>). Retrospective studies conducted separately in Mexico, Netherlands, UK and USA reported an association of reduced IAV-related pneumonia and lower case fatality due to lower respiratory tract IAV infections with statin treatment (<xref rid="B74" ref-type="bibr">74</xref>&#x02013;<xref rid="B77" ref-type="bibr">77</xref>). However, this association was contested in two additional studies that found no benefit of statin treatment on IAV-induced disease burden (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>). This uncertainty regarding the IAV therapeutic potential of these widely used compounds warrants further investigations at the basic science level and in clinical trials.</p></sec></sec><sec id="s3"><title>Perspectives and Future Directions</title><p>The continuous accumulation of adaptive mutations and the introduction of novel viruses in the human population continue to pose a threat to public health, especially to individuals at high risk to influenza. The emergence of strains resistant to existing classes of antiviral drugs and reduced vaccine effectiveness highlights the need for the development of alternative intervention strategies. Therefore, therapeutic approaches that can diminish the potential for drug-resistance while being effective against multiple IAV subtypes/strains are highly desirable. Targeting host cell factors meets these criteria and is more likely to avoid overtly robust immune responses thereby reducing disease severity and improve patient outcome (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Biological response modifiers (BRMs). Potentially therapeutic BRMs that have shown antiviral/immunomodulatory effects during <italic>in vivo</italic> IV infections. Schematic organizing BRMs based on BRM class, host/virus targets, compounds used in cited studies (from innermost to outermost ring). FDA-approved BRMs cited in this review are in bold and italics.</p></caption><graphic xlink:href="fimmu-10-00809-g0001"/></fig><p>A large effort has been made in recent years to identify host proteins to serve as intervention targets against IV infections. Several genetic and proteomic screens have identified several promising hits with potential roles in the IV replication cycle (<xref rid="B80" ref-type="bibr">80</xref>&#x02013;<xref rid="B90" ref-type="bibr">90</xref>). In addition to these genome-wide screens, viral and host protein interactions can be mapped into networks that can also be used to identify host factors critical for IV replication (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>). Interestingly, meta-analysis of some these studies shows limited overlap in the genes/proteins identified as required host factors (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B93" ref-type="bibr">93</xref>&#x02013;<xref rid="B95" ref-type="bibr">95</xref>). This is likely due to study-specific variations in IV types/strains and cell-lines used, inclusion/exclusion criteria, limited hit-validations and methods used to &#x0201c;knock-down/out&#x0201d; these genes.</p><p>Local microenvironment within a given tissue can dictate the quality and intensity of an immune response. Inhibition or activation of critical signaling pathways expressed in both respiratory tract epithelial and immune cells by BRMs can have opposite and unintended consequences. As discussed above, TRAIL regulates immune cell-mediated apoptosis of infected cells and several studies have shown that blocking TRAIL signaling by genomic deletion or depletion by monoclonal antibody administration can improve infection outcome in IAV-infected mice. Indeed inhibition of TRAIL signaling in alveolar macrophages and other monocytes limits their ability to induce apoptosis in alveolar cells, prevents lung tissue damage and promotes survival (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>). However, CD8+ T cells from TRAIL&#x02212;/&#x02212; mice are less able to protect mice from severe infections, consistent with impaired TRAIL-mediated effector functions of CD8+ T cells (<xref rid="B18" ref-type="bibr">18</xref>). Similarly, opposing beneficial and detrimental outcomes have also been observed in studies using Bcl-2 inhibitors to treat IAV infections (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B99" ref-type="bibr">99</xref>).</p><p>BRM delivery should be guided by immune system &#x0201c;compartmentalization&#x0201d; to ensure they elicit balanced immune responses. Ideally, mucosal delivery deposits BRMs that reduce viral titers at the site of IAV replication; however, systemic delivery of certain BRMs might be required to dampen dysregulated responses. This not only depends on the BRMs used but also on the timing of their administration. Moreover, the duration of treatment with BRMs must be considered because sustained inhibition of certain inflammatory responses can result in an immune status that increases susceptibility to secondary opportunistic infections.</p><p>Repurposing of clinically approved drugs could potentially be used as BRMs for the treatment of severe IAV infectious and should be explored (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>). Considering that susceptibility to severe IAV infections is influenced by host genetics and host-specific immune responses, selection of therapeutic BRMs should be carried out using <italic>in vivo</italic> model systems that are representative of the immune status spectrum and underlying conditions of high-risk influenza patients (young, immunocompromised, non-naive, obese, pregnant, or aged). Using these model systems will increase the likelihood of identifying BRMs with clinically relevant antiviral and immunomodulatory potentials.</p></sec><sec id="s4"><title>Author Contributions</title><p>HE, TG, GS, and GR conceptualized and composed the manuscript. GR and HE oversaw all aspects of the manuscript preparation.</p><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>This work was funded by the Alexander von Humboldt Foundation in the framework of the Alexander von Humboldt Professorship endowed by the German Federal Ministry of Education and Research. We apologize to any investigators whose relevant work was not included due to space limitations.</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Sandt</surname><given-names>CE</given-names></name><name><surname>Kreijtz</surname><given-names>JH</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name></person-group>. <article-title>Evasion of influenza A viruses from innate and adaptive immune responses</article-title>. <source>Viruses</source>. (<year>2012</year>) <volume>4</volume>:<fpage>1438</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.3390/v4091438</pub-id><?supplied-pmid 23170167?><pub-id pub-id-type="pmid">23170167</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Goraya</surname><given-names>MU</given-names></name><name><surname>Maarouf</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name></person-group>. <article-title>Host immune response to influenza A virus infection</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>320</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00320</pub-id><?supplied-pmid 29556226?><pub-id pub-id-type="pmid">29556226</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>Innate immunity to virus infection</article-title>. <source>Immunol Rev</source>. (<year>2009</year>) <volume>227</volume>:<fpage>75</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00737.x</pub-id><?supplied-pmid 19120477?><pub-id pub-id-type="pmid">19120477</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasius</surname><given-names>AL</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name></person-group>. <article-title>Intracellular toll-like receptors</article-title>. <source>Immunity</source>. (<year>2010</year>) <volume>32</volume>:<fpage>305</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2010.03.012</pub-id><?supplied-pmid 20346772?><pub-id pub-id-type="pmid">20346772</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>IK</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>Inflammasomes as mediators of immunity against influenza virus</article-title>. <source>Trends Immunol</source>. (<year>2011</year>) <volume>32</volume>:<fpage>34</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2010.11.004</pub-id><?supplied-pmid 21147034?><pub-id pub-id-type="pmid">21147034</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>CJ</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name></person-group>. <article-title>Respiratory epithelial cells in innate immunity to influenza virus infection</article-title>. <source>Cell Tissue Res</source>. (<year>2011</year>) <volume>343</volume>:<fpage>13</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-010-1043-z</pub-id><?supplied-pmid 20848130?><pub-id pub-id-type="pmid">20848130</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Riteau</surname><given-names>B</given-names></name><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name></person-group>. <article-title>Pathogenesis of influenza virus infections: the good, the bad and the ugly</article-title>. <source>Curr Opin Virol</source>. (<year>2012</year>) <volume>2</volume>:<fpage>276</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2012.02.013</pub-id><?supplied-pmid 22709515?><pub-id pub-id-type="pmid">22709515</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Kroeze</surname><given-names>E</given-names></name><name><surname>Fouchier</surname><given-names>RAM</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name></person-group>. <article-title>Pathogenesis of influenza-induced acute respiratory distress syndrome</article-title>. <source>Lancet Infect Dis</source>. (<year>2014</year>) <volume>14</volume>:<fpage>57</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70286-X</pub-id><?supplied-pmid 24239327?><pub-id pub-id-type="pmid">24239327</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambon</surname><given-names>M</given-names></name></person-group>. <article-title>Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy</article-title>. <source>Curr Opin Infect Dis</source>. (<year>2014</year>) <volume>27</volume>:<fpage>560</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/QCO.0000000000000113</pub-id><?supplied-pmid 25333476?><pub-id pub-id-type="pmid">25333476</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>MD</given-names></name><name><surname>Thanh</surname><given-names>TT</given-names></name><name><surname>Khanh</surname><given-names>TH</given-names></name><name><surname>Hien</surname><given-names>VM</given-names></name><name><surname>Smith</surname><given-names>GJD</given-names></name><name><surname>Chau</surname><given-names>NV</given-names></name><etal/></person-group>
<article-title>Brief report - Oseltamivir resistance during treatment of influenza A (H5N1) infection</article-title>. <source>N Engl J Med</source>. (<year>2005</year>) <volume>353</volume>:<fpage>2667</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa054512</pub-id><pub-id pub-id-type="pmid">16371632</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Zaman</surname><given-names>M</given-names></name><name><surname>Adisasmito</surname><given-names>W</given-names></name><name><surname>Coker</surname><given-names>R</given-names></name><name><surname>Hanshaoworakul</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Determinants of antiviral effectiveness in influenza virus A subtype H5N1</article-title>. <source>J Infect Dis</source>. (<year>2012</year>) <volume>206</volume>:<fpage>1359</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis509</pub-id><?supplied-pmid 22927451?><pub-id pub-id-type="pmid">22927451</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>YW</given-names></name><name><surname>Lu</surname><given-names>SH</given-names></name><name><surname>Song</surname><given-names>ZG</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hao</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance</article-title>. <source>Lancet</source>. (<year>2013</year>) <volume>381</volume>:<fpage>2273</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)61125-3</pub-id><?supplied-pmid 23726392?><pub-id pub-id-type="pmid">23726392</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollacott</surname><given-names>AM</given-names></name><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Szretter</surname><given-names>KJ</given-names></name><name><surname>Sloan</surname><given-names>SE</given-names></name><name><surname>Yousofshahi</surname><given-names>M</given-names></name><name><surname>Viswanathan</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks</article-title>. <source>EBioMedicine</source>. (<year>2016</year>) <volume>5</volume>:<fpage>147</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.02.021</pub-id><?supplied-pmid 27077121?><pub-id pub-id-type="pmid">27077121</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>O</given-names></name><name><surname>Takas</surname><given-names>T</given-names></name><name><surname>Nyborg</surname><given-names>AC</given-names></name><name><surname>Jensen</surname><given-names>KM</given-names></name><name><surname>Dubovsky</surname><given-names>F</given-names></name><name><surname>Mallory</surname><given-names>R</given-names></name></person-group>
<article-title>A phase 2a study to evaluate the safety of MEDI8852 in outpatient adults with acute, uncomplicated influenza, A.</article-title>
<source>Open Forum Infect Dis</source>. (<year>2017</year>). <volume>4</volume>(<issue>Suppl. 1</issue>):<issue>S519</issue>
<pub-id pub-id-type="doi">10.1093/ofid/ofx163.1352</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>JM</given-names></name><name><surname>Lim</surname><given-names>JJ</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Derby</surname><given-names>MA</given-names></name><name><surname>Maia</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model</article-title>. <source>Antimicrob Agents Chemother</source>. (<year>2017</year>) <volume>61</volume>:<fpage>e01154</fpage>-<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01154-17</pub-id><?supplied-pmid 28807912?><pub-id pub-id-type="pmid">28807912</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chong</surname><given-names>HC</given-names></name><name><surname>Ng</surname><given-names>SY</given-names></name><name><surname>Kwok</surname><given-names>KW</given-names></name><name><surname>Teo</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>EH</given-names></name><etal/></person-group>. <article-title>Angiopoietin-like 4 increases pulmonary tissue leakiness and damage during influenza pneumonia</article-title>. <source>Cell Rep</source>. (<year>2015</year>) <volume>10</volume>:<fpage>654</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.011</pub-id><?supplied-pmid 25660016?><pub-id pub-id-type="pmid">25660016</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys</article-title>. <source>Clin Infect Dis</source>. (<year>2015</year>) <volume>60</volume>:<fpage>586</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu887</pub-id><?supplied-pmid 25433014?><pub-id pub-id-type="pmid">25433014</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brincks</surname><given-names>EL</given-names></name><name><surname>Katewa</surname><given-names>A</given-names></name><name><surname>Kucaba</surname><given-names>TA</given-names></name><name><surname>Griffith</surname><given-names>TS</given-names></name><name><surname>Legge</surname><given-names>KL</given-names></name></person-group>. <article-title>CD8 T cells utilize TRAIL to control influenza virus infection</article-title>. <source>J Immunol</source>. (<year>2008</year>) <volume>181</volume>:<fpage>4918</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.7.4918</pub-id><?supplied-pmid 18802095?><pub-id pub-id-type="pmid">18802095</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>S</given-names></name><name><surname>Steinmueller</surname><given-names>M</given-names></name><name><surname>von Wulffen</surname><given-names>W</given-names></name><name><surname>Cakarova</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Pleschka</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand</article-title>. <source>J Exp Med</source>. (<year>2008</year>) <volume>205</volume>:<fpage>3065</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20080201</pub-id><?supplied-pmid 19064696?><pub-id pub-id-type="pmid">19064696</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussell</surname><given-names>T</given-names></name><name><surname>Pennycook</surname><given-names>A</given-names></name><name><surname>Openshaw</surname><given-names>PJ</given-names></name></person-group>. <article-title>Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology</article-title>. <source>Eur J Immunol</source>. (<year>2001</year>) <volume>31</volume>:<fpage>2566</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/1521-4141(200109)31:9&#x0003c;2566::AID-IMMU2566&#x0003e;3.0.CO;2-L</pub-id><?supplied-pmid 11536154?><pub-id pub-id-type="pmid">11536154</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlow</surname><given-names>PG</given-names></name><name><surname>Svoboda</surname><given-names>P</given-names></name><name><surname>Mackellar</surname><given-names>A</given-names></name><name><surname>Nash</surname><given-names>AA</given-names></name><name><surname>York</surname><given-names>IA</given-names></name><name><surname>Pohl</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37</article-title>. <source>PLoS ONE</source>. (<year>2011</year>) <volume>6</volume>:<fpage>e25333</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0025333</pub-id><?supplied-pmid 22031815?><pub-id pub-id-type="pmid">22031815</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>HJ</given-names></name><name><surname>Nikapitiya</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Park</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><etal/></person-group>. <article-title>Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>4875</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-04777-4</pub-id><?supplied-pmid 28687749?><pub-id pub-id-type="pmid">28687749</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nacken</surname><given-names>W</given-names></name><name><surname>Ehrhardt</surname><given-names>C</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name></person-group>. <article-title>Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses</article-title>. <source>Biol Chem</source>. (<year>2012</year>) <volume>393</volume>:<fpage>525</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2011-0270</pub-id><?supplied-pmid 22628315?><pub-id pub-id-type="pmid">22628315</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation</article-title>. <source>Biochim Biophys Acta</source>. (<year>2014</year>). <volume>1842</volume>(<issue>12 Pt A</issue>):<fpage>2479</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.04.017</pub-id><?supplied-pmid 24780373?><pub-id pub-id-type="pmid">24780373</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgeling</surname><given-names>Y</given-names></name><name><surname>Schmolke</surname><given-names>M</given-names></name><name><surname>Viemann</surname><given-names>D</given-names></name><name><surname>Nordhoff</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name></person-group>. <article-title>Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection</article-title>. <source>J Biol Chem</source>. (<year>2014</year>) <volume>289</volume>:<fpage>13</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.469239</pub-id><?supplied-pmid 24189062?><pub-id pub-id-type="pmid">24189062</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haasbach</surname><given-names>E</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Ehrhardt</surname><given-names>C</given-names></name><name><surname>Schreiber</surname><given-names>A</given-names></name><name><surname>Pleschka</surname><given-names>S</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity <italic>in vitro</italic> and provides a prolonged treatment window compared to standard of care <italic>in vivo</italic></article-title>. <source>Antiviral Res</source>. (<year>2017</year>) <volume>142</volume>:<fpage>178</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.024</pub-id><?supplied-pmid 28377100?><pub-id pub-id-type="pmid">28377100</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haasbach</surname><given-names>E</given-names></name><name><surname>Reiling</surname><given-names>SJ</given-names></name><name><surname>Ehrhardt</surname><given-names>C</given-names></name><name><surname>Droebner</surname><given-names>K</given-names></name><name><surname>Ruckle</surname><given-names>A</given-names></name><name><surname>Hrincius</surname><given-names>ER</given-names></name><etal/></person-group>. <article-title>The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus</article-title>. <source>Antiviral Res</source>. (<year>2013</year>) <volume>99</volume>:<fpage>336</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.06.008</pub-id><?supplied-pmid 23811282?><pub-id pub-id-type="pmid">23811282</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanguez</surname><given-names>E</given-names></name><name><surname>Hunziker</surname><given-names>A</given-names></name><name><surname>Dobay</surname><given-names>MP</given-names></name><name><surname>Yildiz</surname><given-names>S</given-names></name><name><surname>Schading</surname><given-names>S</given-names></name><name><surname>Elshina</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>3679</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-06119-y</pub-id><?supplied-pmid 30206219?><pub-id pub-id-type="pmid">30206219</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Seo</surname><given-names>YJ</given-names></name><name><surname>Studstill</surname><given-names>CJ</given-names></name><name><surname>Vijayan</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>JJ</given-names></name><name><surname>Hahm</surname><given-names>B</given-names></name></person-group>. <article-title>Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice</article-title>. <source>Antiviral Res</source>. (<year>2018</year>) <volume>158</volume>:<fpage>171</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.08.010</pub-id><?supplied-pmid 30125617?><pub-id pub-id-type="pmid">30125617</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoufache</surname><given-names>K</given-names></name><name><surname>Berri</surname><given-names>F</given-names></name><name><surname>Nacken</surname><given-names>W</given-names></name><name><surname>Vogel</surname><given-names>AB</given-names></name><name><surname>Delenne</surname><given-names>M</given-names></name><name><surname>Camerer</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>PAR1 contributes to influenza A virus pathogenicity in mice</article-title>. <source>J Clin Invest</source>. (<year>2013</year>) <volume>123</volume>:<fpage>206</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1172/JCI61667</pub-id><?supplied-pmid 23202729?><pub-id pub-id-type="pmid">23202729</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budd</surname><given-names>A</given-names></name><name><surname>Alleva</surname><given-names>L</given-names></name><name><surname>Alsharifi</surname><given-names>M</given-names></name><name><surname>Koskinen</surname><given-names>A</given-names></name><name><surname>Smythe</surname><given-names>V</given-names></name><name><surname>Mullbacher</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increased survival after gemfibrozil treatment of severe mouse influenza</article-title>. <source>Antimicrob Agents Chemother</source>. (<year>2007</year>) <volume>51</volume>:<fpage>2965</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00219-07</pub-id><?supplied-pmid 17562808?><pub-id pub-id-type="pmid">17562808</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldridge</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name><surname>Moseley</surname><given-names>CE</given-names></name><name><surname>Boltz</surname><given-names>DA</given-names></name><name><surname>Negovetich</surname><given-names>NJ</given-names></name><name><surname>Reynolds</surname><given-names>C</given-names></name><name><surname>Franks</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.</article-title>
<source>Proc Natl Acad Sci USA</source>. (<year>2009</year>) <volume>106</volume>:<fpage>5306</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0900655106</pub-id><?supplied-pmid 19279209?><pub-id pub-id-type="pmid">19279209</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moseley</surname><given-names>CE</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><name><surname>Aldridge</surname><given-names>JR</given-names></name></person-group>. <article-title>Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice</article-title>. <source>Influenza Other Respir Viruses</source>. (<year>2010</year>) <volume>4</volume>:<fpage>307</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-2659.2010.00155.x</pub-id><?supplied-pmid 20716159?><pub-id pub-id-type="pmid">20716159</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S</given-names></name></person-group>. <article-title>Treating influenza infection, from now and into the future</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>1946</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01946</pub-id><?supplied-pmid 30250466?><pub-id pub-id-type="pmid">30250466</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>YY</given-names></name><name><surname>Pal</surname><given-names>M</given-names></name><name><surname>Chong</surname><given-names>HC</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>MJ</given-names></name><name><surname>Punugu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing</article-title>. <source>J Biol Chem</source>. (<year>2010</year>) <volume>285</volume>:<fpage>32999</fpage>&#x02013;<lpage>3009</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.108175</pub-id><?supplied-pmid 20729546?><pub-id pub-id-type="pmid">20729546</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Ji</surname><given-names>FY</given-names></name><name><surname>Zhao</surname><given-names>YF</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>XJ</given-names></name><etal/></person-group>. <article-title>Role of Angptl4 in vascular permeability and inflammation</article-title>. <source>Inflamm Res</source>. (<year>2014</year>) <volume>63</volume>:<fpage>13</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-013-0678-0</pub-id><?supplied-pmid 24173241?><pub-id pub-id-type="pmid">24173241</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>LA</given-names></name><name><surname>Plowden</surname><given-names>JK</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name><name><surname>Tumpey</surname><given-names>TM</given-names></name></person-group>. <article-title>H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice</article-title>. <source>PLoS Pathog</source>. (<year>2008</year>) <volume>4</volume>:<fpage>e1000115</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000115</pub-id><?supplied-pmid 18670648?><pub-id pub-id-type="pmid">18670648</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narasaraju</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>E</given-names></name><name><surname>Samy</surname><given-names>RP</given-names></name><name><surname>Ng</surname><given-names>HH</given-names></name><name><surname>Poh</surname><given-names>WP</given-names></name><name><surname>Liew</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis</article-title>. <source>Am J Pathol</source>. (<year>2011</year>) <volume>179</volume>:<fpage>199</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.03.013</pub-id><?supplied-pmid 21703402?><pub-id pub-id-type="pmid">21703402</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousefi</surname><given-names>S</given-names></name><name><surname>Mihalache</surname><given-names>C</given-names></name><name><surname>Kozlowski</surname><given-names>E</given-names></name><name><surname>Schmid</surname><given-names>I</given-names></name><name><surname>Simon</surname><given-names>HU</given-names></name></person-group>. <article-title>Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps</article-title>. <source>Cell Death Differ</source>. (<year>2009</year>) <volume>16</volume>:<fpage>1438</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2009.96</pub-id><?supplied-pmid 19609275?><pub-id pub-id-type="pmid">19609275</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julkunen</surname><given-names>I</given-names></name><name><surname>Sareneva</surname><given-names>T</given-names></name><name><surname>Pirhonen</surname><given-names>J</given-names></name><name><surname>Ronni</surname><given-names>T</given-names></name><name><surname>Melen</surname><given-names>K</given-names></name><name><surname>Matikainen</surname><given-names>S</given-names></name></person-group>. <article-title>Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression</article-title>. <source>Cytokine Growth Factor Rev</source>. (<year>2001</year>) <volume>12</volume>:<fpage>171</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/S1359-6101(00)00026-5</pub-id><?supplied-pmid 11325600?><pub-id pub-id-type="pmid">11325600</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>A</given-names></name><name><surname>Shiozaki</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name></person-group>. <article-title>Relevance of signaling molecules for apoptosis induction on influenza A virus replication</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2013</year>) <volume>441</volume>:<fpage>531</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2013.10.100</pub-id><?supplied-pmid 24177013?><pub-id pub-id-type="pmid">24177013</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szretter</surname><given-names>KJ</given-names></name><name><surname>Gangappa</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Shieh</surname><given-names>WJ</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice</article-title>. <source>J Virol</source>. (<year>2007</year>) <volume>81</volume>:<fpage>2736</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02336-06</pub-id><?supplied-pmid 17182684?><pub-id pub-id-type="pmid">17182684</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Leung</surname><given-names>CY</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name></person-group>
<article-title>Innate immune responses to influenza A H5N1: friend or foe?</article-title>
<source>Trends Immunol</source>. (<year>2009</year>) <volume>30</volume>:<fpage>574</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2009.09.004</pub-id><pub-id pub-id-type="pmid">19864182</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>XJ</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name></person-group>. <article-title>New fronts emerge in the influenza cytokine storm</article-title>. <source>Semin Immunopathol</source>. (<year>2017</year>) <volume>39</volume>:<fpage>541</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-017-0636-y</pub-id><?supplied-pmid 28555383?><pub-id pub-id-type="pmid">28555383</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>IN</given-names></name><name><surname>Hartshorn</surname><given-names>KL</given-names></name></person-group>. <article-title>The role of antimicrobial peptides in influenza virus infection and their potential as antiviral and immunomodulatory therapy</article-title>. <source>Pharmaceuticals</source>. (<year>2016</year>) <volume>9</volume>:<fpage>53</fpage>. <pub-id pub-id-type="doi">10.3390/ph9030053</pub-id><?supplied-pmid 27608030?><pub-id pub-id-type="pmid">27608030</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albericio</surname><given-names>F</given-names></name><name><surname>Kruger</surname><given-names>HG</given-names></name></person-group>. <article-title>Therapeutic peptides</article-title>. <source>Future Med Chem</source>. (<year>2012</year>) <volume>4</volume>:<fpage>1527</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.12.94</pub-id><?supplied-pmid 22917241?><pub-id pub-id-type="pmid">22917241</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanetti</surname><given-names>M</given-names></name></person-group>. <article-title>Cathelicidins, multifunctional peptides of the innate immunity</article-title>. <source>J Leukoc Biol</source>. (<year>2004</year>) <volume>75</volume>:<fpage>39</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0403147</pub-id><?supplied-pmid 12960280?><pub-id pub-id-type="pmid">12960280</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>QL</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>FLIP-mediated autophagy regulation in cell death control</article-title>. <source>Nat Cell Biol</source>. (<year>2009</year>) <volume>11</volume>:<fpage>1355</fpage>&#x02013;<lpage>U1225</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1980</pub-id><?supplied-pmid 19838173?><pub-id pub-id-type="pmid">19838173</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohmichi</surname><given-names>M</given-names></name><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Ribon</surname><given-names>V</given-names></name><name><surname>Gazit</surname><given-names>A</given-names></name><name><surname>Levitzki</surname><given-names>A</given-names></name><name><surname>Saltiel</surname><given-names>ARJB</given-names></name></person-group>. <article-title>The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor</article-title>. <source>Biochemistry</source>. (<year>1993</year>) <volume>32</volume>:<fpage>4650</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1021/bi00068a024</pub-id><?supplied-pmid 7683492?><pub-id pub-id-type="pmid">7683492</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieczkarski</surname><given-names>SB</given-names></name><name><surname>Brown</surname><given-names>HA</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group>. <article-title>Role of protein kinase C betaII in influenza virus entry via late endosomes</article-title>. <source>J Virol</source>. (<year>2003</year>) <volume>77</volume>:<fpage>460</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.77.1.460-469.2003</pub-id><?supplied-pmid 12477851?><pub-id pub-id-type="pmid">12477851</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrhardt</surname><given-names>C</given-names></name></person-group>
<article-title>From virus entry to release: the diverse functions of PI3K during RNA virus infections</article-title>. <source>Future Virol</source>. (<year>2011</year>) <volume>6</volume>:<fpage>1225</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.2217/fvl.11.90</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marjuki</surname><given-names>H</given-names></name><name><surname>Gornitzky</surname><given-names>A</given-names></name><name><surname>Marathe</surname><given-names>BM</given-names></name><name><surname>Ilyushina</surname><given-names>NA</given-names></name><name><surname>Aldridge</surname><given-names>JR</given-names></name><name><surname>Desai</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion</article-title>. <source>Cell Microbiol</source>. (<year>2011</year>) <volume>13</volume>:<fpage>587</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2010.01556.x</pub-id><?supplied-pmid 21129142?><pub-id pub-id-type="pmid">21129142</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planz</surname><given-names>O</given-names></name></person-group>. <article-title>Development of cellular signaling pathway inhibitors as new antivirals against influenza</article-title>. <source>Antiviral Res</source>. (<year>2013</year>) <volume>98</volume>:<fpage>457</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.04.008</pub-id><?supplied-pmid 23603495?><pub-id pub-id-type="pmid">23603495</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbahesh</surname><given-names>H</given-names></name><name><surname>Cline</surname><given-names>T</given-names></name><name><surname>Baranovich</surname><given-names>T</given-names></name><name><surname>Govorkova</surname><given-names>EA</given-names></name><name><surname>Schultz-Cherry</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>CJ</given-names></name></person-group>. <article-title>Novel roles of focal adhesion kinase in cytoplasmic entry and replication of influenza A viruses</article-title>. <source>J Virol</source>. (<year>2014</year>) <volume>88</volume>:<fpage>6714</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00530-14</pub-id><?supplied-pmid 24696469?><pub-id pub-id-type="pmid">24696469</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>MS</given-names></name><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>CM</given-names></name><name><surname>Ban</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>NJ</given-names></name><name><surname>Lee</surname><given-names>NR</given-names></name><etal/></person-group>. <article-title>A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2016</year>) <volume>477</volume>:<fpage>311</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.06.111</pub-id><?supplied-pmid 27346133?><pub-id pub-id-type="pmid">27346133</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbahesh</surname><given-names>H</given-names></name><name><surname>Bergmann</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>CJ</given-names></name></person-group>. <article-title>Focal adhesion kinase (FAK) regulates polymerase activity of multiple influenza A virus subtypes</article-title>. <source>Virology</source>. (<year>2016</year>) <volume>499</volume>:<fpage>369</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2016.10.002</pub-id><?supplied-pmid 27743963?><pub-id pub-id-type="pmid">27743963</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ruan</surname><given-names>T</given-names></name><name><surname>Sheng</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Role of c-Jun terminal kinase (JNK) activation in influenza A virus-induced autophagy and replication</article-title>. <source>Virology</source>. (<year>2018</year>) <volume>526</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2018.09.020</pub-id><?supplied-pmid 30316042?><pub-id pub-id-type="pmid">30316042</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meineke</surname><given-names>R</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Elbahesh</surname><given-names>H</given-names></name></person-group>. <article-title>Influenza virus infections and cellular kinases</article-title>. <source>Viruses</source>. (<year>2019</year>) <volume>11</volume>:<fpage>171</fpage>. <pub-id pub-id-type="doi">10.3390/v11020171</pub-id><?supplied-pmid 30791550?><pub-id pub-id-type="pmid">30791550</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchant</surname><given-names>D</given-names></name><name><surname>Singhera</surname><given-names>GK</given-names></name><name><surname>Utokaparch</surname><given-names>S</given-names></name><name><surname>Hackett</surname><given-names>TL</given-names></name><name><surname>Boyd</surname><given-names>JH</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism</article-title>. <source>J Virol</source>. (<year>2010</year>) <volume>84</volume>:<fpage>11359</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00804-10</pub-id><?supplied-pmid 20702616?><pub-id pub-id-type="pmid">20702616</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Droebner</surname><given-names>K</given-names></name><name><surname>Pleschka</surname><given-names>S</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name><name><surname>Planz</surname><given-names>O</given-names></name></person-group>. <article-title>Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Antiviral Res</source>. (<year>2011</year>) <volume>92</volume>:<fpage>195</fpage>&#x02013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.08.002</pub-id><?supplied-pmid 21854809?><pub-id pub-id-type="pmid">21854809</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haasbach</surname><given-names>E</given-names></name><name><surname>Hartmayer</surname><given-names>C</given-names></name><name><surname>Planz</surname><given-names>O</given-names></name></person-group>. <article-title>Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection <italic>in vitro</italic></article-title>. <source>Antiviral Res</source>. (<year>2013</year>) <volume>98</volume>:<fpage>319</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.03.006</pub-id><?supplied-pmid 23523553?><pub-id pub-id-type="pmid">23523553</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>WM</given-names></name><name><surname>Ostertag</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>ZW</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>JNK2 and IKKbeta are required for activating the innate response to viral infection</article-title>. <source>Immunity</source>. (<year>1999</year>) <volume>11</volume>:<fpage>721</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80146-6</pub-id><?supplied-pmid 10626894?><pub-id pub-id-type="pmid">10626894</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Influenza A virus-encoded NS1 virulence factor protein inhibits innate immune response by targeting IKK.</article-title>
<source>Cell Microbiol</source>. (<year>2012</year>) <volume>14</volume>:<fpage>1849</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1111/cmi.12005</pub-id><?supplied-pmid 22891964?><pub-id pub-id-type="pmid">22891964</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leban</surname><given-names>J</given-names></name><name><surname>Baierl</surname><given-names>M</given-names></name><name><surname>Mies</surname><given-names>J</given-names></name><name><surname>Trentinaglia</surname><given-names>V</given-names></name><name><surname>Rath</surname><given-names>S</given-names></name><name><surname>Kronthaler</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>A novel class of potent NF-kappaB signaling inhibitors</article-title>. <source>Bioorg Med Chem Lett</source>. (<year>2007</year>) <volume>17</volume>:<fpage>5858</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.08.022</pub-id><?supplied-pmid 17869512?><pub-id pub-id-type="pmid">17869512</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrhardt</surname><given-names>C</given-names></name><name><surname>Ruckle</surname><given-names>A</given-names></name><name><surname>Hrincius</surname><given-names>ER</given-names></name><name><surname>Haasbach</surname><given-names>E</given-names></name><name><surname>Anhlan</surname><given-names>D</given-names></name><name><surname>Ahmann</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance</article-title>. <source>Cell Microbiol</source>. (<year>2013</year>) <volume>15</volume>:<fpage>1198</fpage>&#x02013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1111/cmi.12108</pub-id><?supplied-pmid 23320394?><pub-id pub-id-type="pmid">23320394</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZM</given-names></name><name><surname>Gao</surname><given-names>E</given-names></name><name><surname>Chuprun</surname><given-names>JK</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name></person-group>. <article-title>GRK2 in the heart: a GPCR kinase and beyond</article-title>. <source>Antioxid Redox Signal</source>. (<year>2014</year>) <volume>21</volume>:<fpage>2032</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2014.5876</pub-id><?supplied-pmid 24702056?><pub-id pub-id-type="pmid">24702056</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitson</surname><given-names>SM</given-names></name></person-group>. <article-title>Regulation of sphingosine kinase and sphingolipid signaling</article-title>. <source>Trends Biochem Sci</source>. (<year>2011</year>) <volume>36</volume>:<fpage>97</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2010.08.001</pub-id><?supplied-pmid 20870412?><pub-id pub-id-type="pmid">20870412</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hait</surname><given-names>NC</given-names></name><name><surname>Oskeritzian</surname><given-names>CA</given-names></name><name><surname>Paugh</surname><given-names>SW</given-names></name><name><surname>Milstien</surname><given-names>S</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name></person-group>. <article-title>Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases</article-title>. <source>Biochimica et Biophysica Acta (BBA) Biomembranes</source>. (<year>2006</year>) <volume>1758</volume>:<fpage>2016</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2006.08.007</pub-id><?supplied-pmid 16996023?><pub-id pub-id-type="pmid">16996023</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>YJ</given-names></name><name><surname>Pritzl</surname><given-names>CJ</given-names></name><name><surname>Vijayan</surname><given-names>M</given-names></name><name><surname>Bomb</surname><given-names>K</given-names></name><name><surname>McClain</surname><given-names>ME</given-names></name><name><surname>Alexander</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Sphingosine kinase 1 serves as a pro-viral factor by regulating viral RNA synthesis and nuclear export of viral ribonucleoprotein complex upon influenza virus infection</article-title>. <source>PLoS ONE</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e75005</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0075005</pub-id><?supplied-pmid 24137500?><pub-id pub-id-type="pmid">24137500</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlin</surname><given-names>SR</given-names></name><name><surname>Camerer</surname><given-names>E</given-names></name></person-group>. <article-title>PARticipation in inflammation</article-title>. <source>J Clin Invest</source>. (<year>2003</year>) <volume>111</volume>:<fpage>25</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1172/JCI17564</pub-id><?supplied-pmid 12511583?><pub-id pub-id-type="pmid">12511583</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>RS</given-names></name><name><surname>Stewart</surname><given-names>GA</given-names></name><name><surname>Goldie</surname><given-names>RG</given-names></name><name><surname>Henry</surname><given-names>PJ</given-names></name></person-group>. <article-title>Altered expression and <italic>in vivo</italic> lung function of protease-activated receptors during influenza A virus infection in mice</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. (<year>2004</year>) <volume>286</volume>:<fpage>L388</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00286.2003</pub-id><?supplied-pmid 14633513?><pub-id pub-id-type="pmid">14633513</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedson</surname><given-names>DS</given-names></name></person-group>. <article-title>Pandemic influenza: a potential role for statins in treatment and prophylaxis</article-title>. <source>Clin Infect Dis</source>. (<year>2006</year>) <volume>43</volume>:<fpage>199</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1086/505116</pub-id><?supplied-pmid 16779747?><pub-id pub-id-type="pmid">16779747</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedson</surname><given-names>DS</given-names></name></person-group>. <article-title>Treating influenza with statins and other immunomodulatory agents</article-title>. <source>Antiviral Res</source>. (<year>2013</year>) <volume>99</volume>:<fpage>417</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.06.018</pub-id><?supplied-pmid 23831494?><pub-id pub-id-type="pmid">23831494</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enserink</surname><given-names>M</given-names></name></person-group>. <article-title>Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap?</article-title>
<source>Science</source>. (<year>2005</year>) <volume>309</volume>:<fpage>1976</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.309.5743.1976a</pub-id><?supplied-pmid 16179440?><pub-id pub-id-type="pmid">16179440</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>FJ</given-names></name><name><surname>Petersen</surname><given-names>H</given-names></name><name><surname>Tollestrup</surname><given-names>K</given-names></name><name><surname>Skipper</surname><given-names>B</given-names></name></person-group>. <article-title>Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins</article-title>. <source>Chest</source>. (<year>2007</year>) <volume>131</volume>:<fpage>1006</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1378/chest.06-1997</pub-id><?supplied-pmid 17426203?><pub-id pub-id-type="pmid">17426203</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo-Esper</surname><given-names>R</given-names></name><name><surname>Sosa-Garcia</surname><given-names>JO</given-names></name><name><surname>Arch-Tirado</surname><given-names>E</given-names></name></person-group>. <article-title>[Experience in the management of the severe form of human influenza A H1N1 pneumonia in an intensive care unit]</article-title>. <source>Cir Cir</source>. (<year>2011</year>) <volume>79</volume>:<fpage>409</fpage>&#x02013;<lpage>16</lpage>.<?supplied-pmid 22385760?><pub-id pub-id-type="pmid">22385760</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandermeer</surname><given-names>ML</given-names></name><name><surname>Thomas</surname><given-names>AR</given-names></name><name><surname>Kamimoto</surname><given-names>L</given-names></name><name><surname>Reingold</surname><given-names>A</given-names></name><name><surname>Gershman</surname><given-names>K</given-names></name><name><surname>Meek</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study</article-title>. <source>J Infect Dis</source>. (<year>2012</year>) <volume>205</volume>:<fpage>13</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jir695</pub-id><?supplied-pmid 22170954?><pub-id pub-id-type="pmid">22170954</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Redelmeier</surname><given-names>DA</given-names></name></person-group>. <article-title>Influenza morbidity and mortality in elderly patients receiving statins: a cohort study</article-title>. <source>PLoS ONE</source>. (<year>2009</year>) <volume>4</volume>:<fpage>e8087</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0008087</pub-id><?supplied-pmid 19956645?><pub-id pub-id-type="pmid">19956645</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>DM</given-names></name><name><surname>Verlander</surname><given-names>NQ</given-names></name><name><surname>Elliot</surname><given-names>AJ</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Gelb</surname><given-names>D</given-names></name><name><surname>Jehring</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006</article-title>. <source>Epidemiol Infect</source>. (<year>2010</year>) <volume>138</volume>:<fpage>1281</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268810000105</pub-id><?supplied-pmid 20109259?><pub-id pub-id-type="pmid">20109259</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Sorensen</surname><given-names>E</given-names></name><name><surname>Nidom</surname><given-names>CA</given-names></name><name><surname>Newton</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Drosophila RNAi screen identifies host genes important for influenza virus replication</article-title>. <source>Nature</source>. (<year>2008</year>) <volume>454</volume>:<fpage>890</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/nature07151</pub-id><?supplied-pmid 18615016?><pub-id pub-id-type="pmid">18615016</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brass</surname><given-names>AL</given-names></name><name><surname>Huang</surname><given-names>IC</given-names></name><name><surname>Benita</surname><given-names>Y</given-names></name><name><surname>John</surname><given-names>SP</given-names></name><name><surname>Krishnan</surname><given-names>MN</given-names></name><name><surname>Feeley</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus</article-title>. <source>Cell</source>. (<year>2009</year>) <volume>139</volume>:<fpage>1243</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.12.017</pub-id><?supplied-pmid 20064371?><pub-id pub-id-type="pmid">20064371</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>SD</given-names></name><name><surname>Gat-Viks</surname><given-names>I</given-names></name><name><surname>Shum</surname><given-names>BO</given-names></name><name><surname>Dricot</surname><given-names>A</given-names></name><name><surname>de Grace</surname><given-names>MM</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection</article-title>. <source>Cell</source>. (<year>2009</year>) <volume>139</volume>:<fpage>1255</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.12.018</pub-id><?supplied-pmid 20064372?><pub-id pub-id-type="pmid">20064372</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>BQ</given-names></name><name><surname>Bamba</surname><given-names>D</given-names></name><name><surname>Weng</surname><given-names>K</given-names></name><name><surname>Ung</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>SJ</given-names></name><name><surname>Van Dyke</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza</article-title>. <source>Virology</source>. (<year>2009</year>) <volume>387</volume>:<fpage>473</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.02.046</pub-id><?supplied-pmid 19327807?><pub-id pub-id-type="pmid">19327807</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlas</surname><given-names>A</given-names></name><name><surname>Machuy</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>Y</given-names></name><name><surname>Pleissner</surname><given-names>KP</given-names></name><name><surname>Artarini</surname><given-names>A</given-names></name><name><surname>Heuer</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication</article-title>. <source>Nature</source>. (<year>2010</year>) <volume>463</volume>:<fpage>818</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nature08760</pub-id><?supplied-pmid 20081832?><pub-id pub-id-type="pmid">20081832</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konig</surname><given-names>R</given-names></name><name><surname>Stertz</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Human host factors required for influenza virus replication</article-title>. <source>Nature</source>. (<year>2010</year>) <volume>463</volume>:<fpage>813</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature08699</pub-id><?supplied-pmid 20027183?><pub-id pub-id-type="pmid">20027183</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripp</surname><given-names>RA</given-names></name><name><surname>Mark Tompkins</surname><given-names>S</given-names></name></person-group>. <article-title>Antiviral effects of inhibiting host gene expression</article-title>. <source>Curr Top Microbiol Immunol</source>. (<year>2015</year>) <volume>386</volume>:<fpage>459</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/82_2014_409</pub-id><?supplied-pmid 25007848?><pub-id pub-id-type="pmid">25007848</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group>. <article-title>Influenza virus-host interactomes as a basis for antiviral drug development</article-title>. <source>Curr Opin Virol</source>. (<year>2015</year>) <volume>14</volume>:<fpage>71</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2015.08.008</pub-id><?supplied-pmid 26364134?><pub-id pub-id-type="pmid">26364134</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Perez</surname><given-names>JT</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Benitez</surname><given-names>A</given-names></name><name><surname>Kandasamy</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Genome-wide CRISPR/Cas9 screen identifies host factors essential for influenza virus replication</article-title>. <source>Cell Rep</source>. (<year>2018</year>) <volume>23</volume>:<fpage>596</fpage>&#x02013;<lpage>607</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.045</pub-id><?supplied-pmid 29642015?><pub-id pub-id-type="pmid">29642015</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>HR</given-names></name></person-group>. <article-title>Repurposing host-based therapeutics to control coronavirus and influenza virus</article-title>. <source>Drug Discov Today</source>. (<year>2019</year>) <volume>24</volume>:<fpage>726</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2019.01.018</pub-id><?supplied-pmid 30711575?><pub-id pub-id-type="pmid">30711575</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzorno</surname><given-names>A</given-names></name><name><surname>Terrier</surname><given-names>O</given-names></name><name><surname>Nicolas de Lamballerie</surname><given-names>C</given-names></name><name><surname>Julien</surname><given-names>T</given-names></name><name><surname>Padey</surname><given-names>B</given-names></name><name><surname>Traversier</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>60</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00060</pub-id><?supplied-pmid 30761132?><pub-id pub-id-type="pmid">30761132</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Patil</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Dorf</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Comparative influenza protein interactomes identify the role of plakophilin 2 in virus restriction</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>13876</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms13876</pub-id><?supplied-pmid 28169297?><pub-id pub-id-type="pmid">28169297</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname><given-names>EE</given-names></name><name><surname>Kawakami</surname><given-names>E</given-names></name><name><surname>Katoh</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Network-guided discovery of influenza virus replication host factors</article-title>. <source>MBio</source>. (<year>2018</year>) <volume>9</volume>:<fpage>e02002</fpage>-<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.02002-18</pub-id><?supplied-pmid 30563907?><pub-id pub-id-type="pmid">30563907</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group>. <article-title>Cellular networks involved in the influenza virus life cycle</article-title>. <source>Cell Host Microbe</source>. (<year>2010</year>) <volume>7</volume>:<fpage>427</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2010.05.008</pub-id><?supplied-pmid 20542247?><pub-id pub-id-type="pmid">20542247</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Chassey</surname><given-names>B</given-names></name><name><surname>Meyniel-Schicklin</surname><given-names>L</given-names></name><name><surname>Aublin-Gex</surname><given-names>A</given-names></name><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Lotteau</surname><given-names>V</given-names></name></person-group>. <article-title>Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery</article-title>. <source>Mol Biosyst</source>. (<year>2012</year>) <volume>8</volume>:<fpage>1297</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1039/c2mb05416g</pub-id><?supplied-pmid 22307679?><pub-id pub-id-type="pmid">22307679</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>Pohl</surname><given-names>MO</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Rodriguez-Frandsen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Stein</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Meta- and orthogonal integration of influenza &#x0201c;OMICs&#x0201d; data defines a role for UBR4 in virus budding</article-title>. <source>Cell Host Microbe</source>. (<year>2015</year>) <volume>18</volume>:<fpage>723</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2015.11.002</pub-id><?supplied-pmid 26651948?><pub-id pub-id-type="pmid">26651948</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brincks</surname><given-names>EL</given-names></name><name><surname>Gurung</surname><given-names>P</given-names></name><name><surname>Langlois</surname><given-names>RA</given-names></name><name><surname>Hemann</surname><given-names>EA</given-names></name><name><surname>Legge</surname><given-names>KL</given-names></name><name><surname>Griffith</surname><given-names>TS</given-names></name></person-group>. <article-title>The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL.</article-title>
<source>J Immunol</source>. (<year>2011</year>) <volume>187</volume>:<fpage>4581</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1002241</pub-id><?supplied-pmid 21940678?><pub-id pub-id-type="pmid">21940678</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>McCabe</surname><given-names>TM</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name></person-group>. <article-title>Pathogenic potential of interferon alphabeta in acute influenza infection</article-title>. <source>Nat Commun</source>. (<year>2014</year>) <volume>5</volume>:<fpage>3864</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms4864</pub-id><?supplied-pmid 24844667?><pub-id pub-id-type="pmid">24844667</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakkola</surname><given-names>L</given-names></name><name><surname>Denisova</surname><given-names>OV</given-names></name><name><surname>Tynell</surname><given-names>J</given-names></name><name><surname>Viiliainen</surname><given-names>J</given-names></name><name><surname>Ysenbaert</surname><given-names>T</given-names></name><name><surname>Matos</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice</article-title>. <source>Cell Death Dis</source>. (<year>2013</year>) <volume>4</volume>:<fpage>e742</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.267</pub-id><?supplied-pmid 23887633?><pub-id pub-id-type="pmid">23887633</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulanova</surname><given-names>D</given-names></name><name><surname>Ianevski</surname><given-names>A</given-names></name><name><surname>Bugai</surname><given-names>A</given-names></name><name><surname>Akimov</surname><given-names>Y</given-names></name><name><surname>Kuivanen</surname><given-names>S</given-names></name><name><surname>Paavilainen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins</article-title>. <source>Viruses</source>. (<year>2017</year>) <volume>9</volume>:<fpage>271</fpage>. <pub-id pub-id-type="doi">10.3390/v9100271</pub-id><?supplied-pmid 28946654?><pub-id pub-id-type="pmid">28946654</pub-id></mixed-citation></ref></ref-list></back></article>